TTC21B

Across TCGA pan-cancer cohorts, TTC21B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TTC21B data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TTC21B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC21B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, LUAD, and LIHC are the cancer types where TTC21B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	38	view →
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	26	view →
LIHC	DFS	Median	All	0.077	0.543	.002	18	view →
UCEC	OS	Median	II,III,IV	0.892	0.454	.023	14	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	12	view →
KIRC	DFS	Median	All	0.146	0.808	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TTC21B–LUSC (DFS)

Open the LUSC breakdown →